RU2744909C2 - Способ лечения или предотвращения инсульта - Google Patents

Способ лечения или предотвращения инсульта Download PDF

Info

Publication number
RU2744909C2
RU2744909C2 RU2017120031A RU2017120031A RU2744909C2 RU 2744909 C2 RU2744909 C2 RU 2744909C2 RU 2017120031 A RU2017120031 A RU 2017120031A RU 2017120031 A RU2017120031 A RU 2017120031A RU 2744909 C2 RU2744909 C2 RU 2744909C2
Authority
RU
Russia
Prior art keywords
vegf
compound
stroke
antibody
seq
Prior art date
Application number
RU2017120031A
Other languages
English (en)
Russian (ru)
Other versions
RU2017120031A3 (enExample
RU2017120031A (ru
Inventor
Ульф ЭРИКССОН
Ингрид НИЛЬССОН
Дэниел ЛОУРЕНС
Эньмин Джо СУ
Original Assignee
СиЭсЭл ЛИМИТЕД
Б-Креатив Сведен Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014904606A external-priority patent/AU2014904606A0/en
Application filed by СиЭсЭл ЛИМИТЕД, Б-Креатив Сведен Аб filed Critical СиЭсЭл ЛИМИТЕД
Publication of RU2017120031A publication Critical patent/RU2017120031A/ru
Publication of RU2017120031A3 publication Critical patent/RU2017120031A3/ru
Application granted granted Critical
Publication of RU2744909C2 publication Critical patent/RU2744909C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24029—Aureolysin (3.4.24.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
RU2017120031A 2014-11-17 2015-11-17 Способ лечения или предотвращения инсульта RU2744909C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904606A AU2014904606A0 (en) 2014-11-17 Method of treating or preventing stroke
AU2014904606 2014-11-17
PCT/AU2015/050720 WO2016077878A1 (en) 2014-11-17 2015-11-17 Method of treating or preventing stroke

Publications (3)

Publication Number Publication Date
RU2017120031A RU2017120031A (ru) 2018-12-19
RU2017120031A3 RU2017120031A3 (enExample) 2019-05-15
RU2744909C2 true RU2744909C2 (ru) 2021-03-17

Family

ID=56012959

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017120031A RU2744909C2 (ru) 2014-11-17 2015-11-17 Способ лечения или предотвращения инсульта

Country Status (12)

Country Link
US (2) US10336821B2 (enExample)
EP (1) EP3220952B1 (enExample)
JP (1) JP6863892B2 (enExample)
KR (1) KR102560025B1 (enExample)
CN (1) CN107106681B (enExample)
AU (1) AU2015349610B2 (enExample)
CA (1) CA2967070C (enExample)
DK (1) DK3220952T3 (enExample)
ES (1) ES2881303T3 (enExample)
PL (1) PL3220952T3 (enExample)
RU (1) RU2744909C2 (enExample)
WO (1) WO2016077878A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
US20190076510A1 (en) * 2017-09-13 2019-03-14 The Regents Of The University Of Michigan Protein kinase c inhibition to extend tissue plasminogen activator treatment for ischemic disease
US20210179721A1 (en) * 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
CN105979965B (zh) 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAGBERG C. E. et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes //Nature, 2012, Т. 490, N. 7420. *
MEDVEDEVA E. V. et al. Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain //Journal of Molecular Neuroscience, 2013, Т. 49, N. 2. *
SOLIMAN S. et al. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B //Journal of Pharmacology and Experimental Therapeutics, 2014, Т. 349, N. 3. *

Also Published As

Publication number Publication date
CA2967070C (en) 2024-03-12
EP3220952A4 (en) 2018-03-28
AU2015349610B2 (en) 2021-08-26
WO2016077878A1 (en) 2016-05-26
PL3220952T3 (pl) 2022-01-31
JP2017535551A (ja) 2017-11-30
EP3220952B1 (en) 2021-04-21
KR102560025B1 (ko) 2023-07-26
RU2017120031A3 (enExample) 2019-05-15
EP3220952A1 (en) 2017-09-27
CA2967070A1 (en) 2016-05-26
US20190315849A1 (en) 2019-10-17
BR112017010336A2 (pt) 2018-05-15
ES2881303T3 (es) 2021-11-29
KR20170082631A (ko) 2017-07-14
DK3220952T3 (da) 2021-07-19
US20180237513A1 (en) 2018-08-23
US10336821B2 (en) 2019-07-02
JP6863892B2 (ja) 2021-04-21
US10961304B2 (en) 2021-03-30
CN107106681A (zh) 2017-08-29
CN107106681B (zh) 2021-11-09
RU2017120031A (ru) 2018-12-19
AU2015349610A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
US11773171B2 (en) WNT surrogate molecules and uses thereof
US20240002488A1 (en) Method of treating or preventing liver conditions
JP2002505097A (ja) 治療薬としてのｃｄ１４７結合分子
CN102725309A (zh) 针对GPVI的新的拮抗剂抗体及其Fab片段及其用途
JP7813234B2 (ja) 抗ｔｍｐｒｓｓ６抗体及びその用途
JP2020029459A (ja) 腎症を処置する方法
EP3981787A1 (en) Anti-connective tissue growth factor antibody and application thereof
EP3901173A1 (en) Bispecific protein
KR102466794B1 (ko) 상처 치료 방법
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
HK1242603B (en) Method of treating or preventing stroke
BR112017010336B1 (pt) Uso de um composto que inibe a sinalização de vegf-b

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant